Agenus jumps on cancer drug partnership with India's Zydus
View all comments(0)
Shares of cancer therapy developer Agenus AGEN.O rise 33.4% to $5.51 premarket
AGEN and India-based Zydus Lifesciences ZYDU.NS have entered a $141 mln partnership to advance cancer immunotherapy drugs
Agenus will receive $75 mln upfront and potentially $50 mln more from Zydus for transferring its biologics manufacturing facilities, the cos say
Zydus is making a $16 mln equity investment in Agenus by purchasing shares at $7.50 each
As of last close, AGEN up 50.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Hantavirus Appears Sporadically, Is Now the Opportunity to Buy Vaccine Concept Stock Moderna?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.